News

The US Food and Drug Administration (FDA) has extended the review period for AbbVie’s supplemental New Drug Application (sNDA) for upadacitinib. The global R&D-based biopharmaceutical company’s new drug

The UK’s Cambridge-based biopharma company AstraZeneca will be delivering 500,000 more doses of AZD7442 to the US after having modified an existing agreement with the US Government. AstraZeneca’s

The US Food and Drug Administration (FDA) has granted priority review for Merck’s New Drug Application (NDA) for the hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan. A candidate from

California-based biopharmaceutical company Gilead Sciences, Inc. and New Jersey-based Merck have announced their agreement to develop and commercialise the long-acting HIV treatments lenacapavir and islatravir. The treatments combine

Japan-based, R&D-driven Takeda Pharmaceutical Company Limited has submitted a New Drug Application (NDA) for lanadelumab to the Ministry of Health, Labour and Welfare (MHLW) in Japan. Lanadelumab subcutaneous injection

A branch of the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID) has granted $2.5m to 12 institutes across the world for

Enveric Biosciences has announced that it has signed an exclusive, perpetual licensing agreement with Diverse Biotech to develop new molecules for the treatment of cancer and other debilitating

Japan-based Takeda Pharmaceutical Company Limited has entered into an agreement to acquire private biopharmaceutical company Maverick Therapeutics, Inc. in a bid to expand its novel immuno-oncology portfolio. California,

Eli Lilly and Company has signed a research collaboration and license agreement with Biolojic Design to discover and develop therapies for diabetes treatment. Under the deal, Biolojic’s artificial